SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-002169
Filing Date
2023-11-02
Accepted
2023-11-02 16:06:13
Documents
61
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20230930x10q.htm   iXBRL 10-Q 1301969
2 EX-31.1 cldx-20230930xex31d1.htm EX-31.1 14901
3 EX-31.2 cldx-20230930xex31d2.htm EX-31.2 14945
4 EX-32.1 cldx-20230930xex32d1.htm EX-32.1 8729
  Complete submission text file 0001410578-23-002169.txt   5978718

Data Files

Seq Description Document Type Size
5 EX-101.SCH cldx-20230930.xsd EX-101.SCH 31363
6 EX-101.CAL cldx-20230930_cal.xml EX-101.CAL 41304
7 EX-101.DEF cldx-20230930_def.xml EX-101.DEF 136784
8 EX-101.LAB cldx-20230930_lab.xml EX-101.LAB 332993
9 EX-101.PRE cldx-20230930_pre.xml EX-101.PRE 235299
55 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20230930x10q_htm.xml XML 1254457
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 231372234
SIC: 2835 In Vitro & In Vivo Diagnostic Substances